ArticleNutrition & metabolism2007
Atheroprotective natural anti-phosphorylcholine antibodies of IgM subclass are decreased in Swedish controls as compared to non-westernized individuals from New Guinea.
Article in Nutrition & metabolism, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 59 citations in OpenAlex.
- Different subclasses and isotypes of antibodies against phosphorylcholine in haemodialysis patients: association with mortality.Clinical and experimental immunology · 2020Trial
- Gluten-free vegan diet induces decreased LDL and oxidized LDL levels and raised atheroprotective natural antibodies against phosphorylcholine in patients with rheumatoid arthritis: a randomized study.Arthritis research & therapy · 2008Trial
- Antibodies Against Phosphorylcholine in Prediction of Cardiovascular Disease Among Women: A Population-Based Prospective Cohort Study.JACC. Advances · 2024Article
- Article
- Antibodies against oxidation-specific epitopes and risk of acute myocardial infarction.Journal of lipid research · 2023Article
- Systemic lupus erythematosus and cardiovascular disease.Journal of internal medicine · 2023Review
- Antibodies in action: the role of humoral immunity in the fight against atherosclerosis.Immunity & ageing : I & A · 2022Review
- Antibodies Against Phosphorylcholine Among 60-Year-Olds: Clinical Role and Simulated Interactions.Frontiers in cardiovascular medicine · 2022Article
- Antibodies against phosphorylcholine in hospitalized versus non-hospitalized obese subjects.Scientific reports · 2021Observational
- Higher levels of anti-phosphorylcholine autoantibodies in early rheumatoid arthritis indicate lower risk of incident cardiovascular events.Arthritis research & therapy · 2021Article
- Potential natural immunization against atherosclerosis in hibernating bears.Scientific reports · 2021Article
- C-reactive protein in traditional melanesians on Kitava.BMC cardiovascular disorders · 2020Article
- Article
- Immunoglobulin G1 Antibodies Against Phosphorylcholine Are Associated With Protection in Systemic Lupus Erythematosus and Atherosclerosis: Potential Underlying Mechanisms.ACR open rheumatology · 2020Article
- Glycan Reactive Natural Antibodies and Viral Immunity.Viral immunology · 2020Review
- Article
- The Contribution of Autoantibodies to Inflammatory Cardiovascular Pathology.Frontiers in immunology · 2018Review
- Cardiovascular disease and type 2 diabetes in evolutionary perspective: a critical role for helminths?Evolution, medicine, and public health · 2016Review
- IgM-antibodies against phosphorylcholine in mothers and normal or low birth weight term newborn infants.PloS one · 2014Article
- Glucose impairs B-1 cell function in diabetes.Clinical and experimental immunology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine the importance of IgM antibodies against phosphorylcholine (aPC), a novel protective factor for cardiovascular disease (CVD), in a population with a non-western life style as compared with a Swedish control group. METHODS AND
resultsRisk factors for cardiovascular disease were determined in a group of 108 individuals aged 40-86 years from New Guinea and 108 age-and sex-matched individuals from a population based study in Sweden. Antibodies were tested by ELISA. aPC IgM levels were significantly higher among New Guineans than among Swedish controls (p < 0.0001). This difference remained significant among both men and women when controlled for LDL and blood pressure which were lower and smoking which was more prevalent in New Guineans as compared to Swedish controls (p < 0.0001). aPC IgM was significantly and negatively associated with age and systolic blood pressure among Swedish controls and with waist circumference among New Guineans. aPC IgM levels were significantly higher among women than men in both groups. The proportion of the saturated fatty acid (FA) myristic acid in serum cholesterol esters was negatively but polyunsaturated eicosapentaenoic acid and also lipoprotein (a) were positively associated with aPC IgM levels.
conclusionIgM-antibodies against PC, which have atheroprotective properties, are higher in a population from Kitava, New Guinea with a traditional lifestyle, than in Swedish Controls, and higher among women than men in both populations tested. Such antibodies could contribute to the low incidence of cardiovascular disease reported from Kitava and could also provide an explanation as to why women have a later onset of CVD than men.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.